Coformulated Bictegravir/Emtricitabine/Tenofovir Alafenamide for Postexposure Prophylaxis After Sexual Assault: A Retrospective Real-World Study.

Autor: Teresita de Jesús CL; Department of Gynecology and Care for Victims of Sexual Assault, Clínica Especializada Condesa Iztapalapa, Mexico City, Mexico., Edgar PB; Department of Infectious Diseases, Clínica Especializada Condesa Iztapalapa, Mexico City, Mexico., Carlos Ruben NC; Department of Gynecology and Care for Victims of Sexual Assault, Clínica Especializada Condesa Iztapalapa, Mexico City, Mexico., Marla TR; Department of Mental Health, Clínica Especializada Condesa Iztapalapa, Mexico City, Mexico., Juan Carlos RA; Department of Infectious Diseases, Clínica Especializada Condesa Iztapalapa, Mexico City, Mexico., Raúl Adrián CF; Department of Epidemiology, Clínica Especializada Condesa Iztapalapa, Mexico City, Mexico., Andrea GR; Medical Director, Clínica Especializada Condesa, Mexico City, Mexico.
Jazyk: angličtina
Zdroj: Open forum infectious diseases [Open Forum Infect Dis] 2024 Jul 25; Vol. 11 (8), pp. ofae436. Date of Electronic Publication: 2024 Jul 25 (Print Publication: 2024).
DOI: 10.1093/ofid/ofae436
Abstrakt: We report the experience of bictegravir/emtricitabine/tenofovir alafenamide for nonoccupational postexposure prophylaxis in sexual assault cases. Between June 2021 and October 2023, 39 individuals completed the 28-day follow-up; 41% experienced some side effects, and 1 person discontinued the drug because of a rash. No individuals seroconverted to HIV during the follow-up period.
Competing Interests: Potential conflicts of interest. All authors: No reported conflicts.
(© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje